Friday, July 10, 2026

Drug profile · INN

vepdegestrant

vepdegestrant (VEPPANU) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 3
News articles 5
Drug details — vepdegestrant

Quick answer

vepdegestrant (VEPPANU) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN vepdegestrant
Brand VEPPANU
Route ORAL
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Recent coverage

FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer
High impact Newsestrogen receptor-positive, HER2-negative breast cancerJun 11, 2026

FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer

FDA · estrogen receptor-positive, HER2-negative breast cancer · 6 min

The FDA approved vepdegestrant (Veppanu) on May 1, 2026 for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. For BD teams and investors, the key read-through is a new catalyst tied to an FDA-labeled oral protein degrader and a clearly defined biomarker-selected population.

Dr. Sarah Mitchell
Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU
High impact Newsbreast cancerJun 1, 2026

Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU

FDA · breast cancer · 7 min

Rigel Pharmaceuticals has successfully licensed VEPPANU, an FDA-approved drug for breast cancer, marking a significant milestone in its growth strategy.

Dr. Sarah Mitchell
Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
Critical impact NewsOncology - Advanced Breast CancerMay 4, 2026

Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer

FDA · Oncology - Advanced Breast Cancer · 3 min

Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.

Dr. Laura Bennett
FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant
High impact Analysisadvanced or metastatic HR-positive, HER2-negative breast cancerMay 4, 2026

FDA Approval for Pfizer's Breast Cancer Drug: Vepdegestrant

FDA · advanced or metastatic HR-positive, HER2-negative breast cancer · 13 min

The FDA has granted approval for Pfizer and Arvinas' novel breast cancer drug, vepdegestrant. This marks a significant new treatment option for patients with advanced or metastatic HR-positive, HER2-negative breast cancer who have exhausted prior endocrine therapies.

Kenji Watanabe

Pipeline programs

  1. A Study to Learn If the Study Medicine Called... Phase 1 · First Biotech (Australia) · ER+/HER2 positive breast cancer
  2. C4891037 Phase 1 · First Biotech (Australia) · ER+/HER2- breast cancer
  3. C4891038 Phase 1 · First Biotech (Australia) · ER+/HER2- Breast Cancer

Frequently asked questions

What is vepdegestrant?

vepdegestrant (VEPPANU) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for vepdegestrant?

VEPPANU is a marketed brand name for vepdegestrant. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of vepdegestrant?

vepdegestrant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.